NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Actuate Therapeutics Inc.
Dragonfly Therapeutics
Akeso
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Shanghai Yizhong Pharmaceutical Co., Ltd.
Arcus Biosciences, Inc.
OncoSec Medical Incorporated
Corcept Therapeutics
Eli Lilly and Company
Prescient Therapeutics, Ltd.
EpiAxis Therapeutics